Compositions and methods for fumonisin detoxification

Details Compositions and methods for fumonisin detoxification Compositions and methods for fumonisin detoxification

2000-10-02

2003-03-18

Ketter, James (Department: 1636)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using a micro-organism to make a protein or polypeptide

C435S252300, C435S320100, C435S196000, C536S023100, C536S023200, C536S024100, C424S093100

Reexamination Certificate

active

06534291

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to compositions and methods for detoxification or degradation of fumonisin or AP1. The method has broad application in agricultural biotechnology and crop agriculture and in the improvement of food grain quality.
BACKGROUND OF THE INVENTION
Fungal diseases are common problems in crop agriculture. Many strides have been made against plant diseases as exemplified by the use of hybrid plants, pesticides, and improved agricultural practices. However, as any grower or home gardener can attest, the problems of fungal plant disease continue to cause difficulties in plant cultivation. Thus, there is a continuing need for new methods and materials for solving the problems caused by fungal diseases of plants.
These problems can be met through a variety of approaches. For example, the infectious organisms can be controlled through the use of agents that are selectively biocidal for the pathogens. Another method is interference with the mechanism by which the pathogen invades the host crop plant. Yet another method, in the case of pathogens that cause crop losses, is interference with the mechanism by which the pathogen causes injury to the host crop plant. In the case of pathogens that produce toxins that are undesirable to mammals or other animals that feed on the crop plants, interference with toxin production, storage, or activity can be beneficial.
Since their discovery and structural elucidation in 1988 (Bezuidenhout et al. (1988)
Journal Chem. Soc., Chem. Commun.
1988:743-745), fumonisins have been recognized as a potentially serious problem in maize-fed livestock. They are linked to several animal toxicoses including leukoencephalomalacia (Marasas et al. (1988)
Onderstepoort J. Vet. Res.
55:197-204; Wilson et al. (1990)
American Association of Veterinary Laboratory Diagnosticians: Abstracts
33
rd Annual Meeting,
Denver, Colo., Madison, Wis., USA) and porcine pulmonary edema (Colvin et al. (1992)
Mycopathologia
11 7:79-82). Fumonisins are also suspected carcinogens (Geary et al. (1971)
Coord. Chem. Rev.
7:81; Gelderblom et al. (1991)
Carcinogenesis
12:1247-1251; Gelderblom et al. (1992)
Carcinogenesis
13:433-437). Fusarium isolates in section Liseola produce fumonisins in culture at levels from 2 to >4000 ppm (Leslie et al. (1992)
Phytopathology
82:341-345). Isolates from maize (predominantly mating population A) are among the highest producers of fumonisin (Leslie et al., supra). Fumonisin levels detected in field-grown maize have fluctuated widely depending on location and growing season, but both preharvest and postharvest surveys of field maize have indicated that the potential for high levels of fumonisins exists (Murphy et al. (1993)
J. Agr. Food Chem.
41:263-266). Surveys of food and feed products have also detected fumonisin (Holcomb et al. (1993)
J. Agr. Food Chem.
41:764-767; Hopmans et al. (1993)
J. Agr. Food Chem.
41:1655-1658); Sydenham et al. (1991)
J. Agr. Food Chem.
39:2014-2018). The etiology of Fusarium ear mold is poorly understood, although physical damage to the ear and certain environmental conditions can contribute to its occurrence (Nelson et al. (1992)
Mycopathologia
117:29-36). Fusarium can be isolated from most field grown maize, even when no visible mold is present. The relationship between seedling infection and stalk and ear diseases caused by Fusarium is not clear. Genetic resistance to visible kernel mold has been identified (Gendloff et al. (1986)
Phytopathology
76:684-688; Holley et al. (1989)
Plant Dis.
73:578-580), but the relationship to visible mold to fumonisin production has yet to be elucidated.
Fumonisins have been shown in in vitro mammalian cell studies to inhibit sphingolipid biosynthesis through inhibition of the enzyme sphingosine N-acetyl transferase, resulting in the accumulation of the precursor sphinganine (Norred et al. (1992)
Mycopathologia
117:73-78; Wang et al. (1991)
Biol. Chem.
266:14486; Yoo et al. (1992)
Toxicol. Appl. Pharmacol.
114:9-15; Nelson et al. (1993)
Annu. Rev. Phytpathol.
31:233-252). It is likely that inhibition of this pathway accounts for at least some of fumonisin's toxicity, and support for this comes from measures of sphinganine:sphingosine ratios in animals fed purified fumonisin (Wang et al. (1992)
J. Nutr.
122:1706-1716). Fumonisins also affect plant cell growth (Abbas et al. (1992)
Weed Technol.
6:548-552; Van Asch et al. (1992)
Phytopathology
82:1330-1332; Vesonder et al. (1992)
Arch. Environ. Contam. Toxicol.
23:464-467). Kuti et al. (1993) (Abstract, Annual Meeting American Phytopathological Society, Memphis, Tenn.: APS Press) reported on the ability of exogenously added fumonisins to accelerate disease development and increase sporulation of
Fusarium moniliform
and
F. oxysporum
on tomato.
Enzymes that degrade the fungal toxin fumonisin to the compound AP1 have been identified in U.S. Pat. No. 5,716,820 and pending U.S. patent application Ser. Nos. 08/888,949 and 08/888,950, both filed Jul. 7, 1997, and hereby incorporated by reference. Plants expressing a fumonisin esterase enzyme, infected by fumonisin producing fungus, and tested for fumonisin and AP1 were found to have low levels of fumonisin but high levels of AP1. AP1 is less toxic than fumonisin to plants and probably also animals, but contamination with AP1 is still a concern. The best result would be complete detoxification of fumonisin to a non-toxic form. Therefore enzymes capable of degrading AP1 are necessary for the further detoxification of fumonisin.
SUMMARY OF THE INVENTION
Compositions and methods for catabolism and detoxification of fumonisin and fumonisin-degradation products as well as fumonisin-related toxins are provided. In particular, proteins involved in catabolism and transmembrane transport of fumonisin and fumonisin catabolic products are provided. Nucleotide sequences corresponding to the proteins are also included. The compositions are useful in the detoxification and degradation of fumonisin. The nucleotide sequences can be used in expression cassettes for transformation of host cells of interest. The compositions and methods of the invention are steps in a catabolic pathway for fumonisin. Thus, organisms can be genetically modified to provide for the catabolism and detoxification of fumonisin and fumonisin-related toxins.
In particular, expression cassettes for expression of the enzymes in plants and other organisms are provided as well as transformed plants and other host cells.


REFERENCES:
patent: 5178863 (1993-01-01), Toyoda et al.
patent: 5639949 (1997-06-01), Ligon et al.
patent: 5716820 (1998-02-01), Duvick et al.
patent: 5792931 (1998-08-01), Duvick et al.
patent: 5877273 (1999-03-01), Hance et al.
patent: 0712932 (1996-05-01), None
patent: WO 95/06121 (1995-03-01), None
patent: WO 95/06128 (1995-03-01), None
patent: WO 96/06175 (1996-02-01), None
patent: WO 96/12414 (1996-05-01), None
patent: WO 96/20595 (1996-07-01), None
patent: WO 99/02703 (1999-01-01), None
patent: WO 99/10514 (1999-03-01), None
patent: WO 99/32505 (1999-07-01), None
Keller and Sullivan, J. Agric. Food Chem. (1998) 46:2823-2826.*
Anzai et al. (1989) “Transgenic Tobacco Resistant To A Bacterial Disease By The Detoxification Of A Pathogenic Toxin”,Mol Gen Genet 219:492-494, ISSN: 0026-3924, XP002083624.
Anzai et al. (Jan. 1, 1989) “Transgenic tobacco resistant to a bacterial disease by the detoxification of a pathogenic toxin”,Molecular and General Genetics 219:492-494, XP002083624, ISSN: 0026-3925 the whole document.
Armengaud (Sep. 17, 1998) “Shingomonas sp. ORFs G1, G3 to G8 and EDO2gene”, EMBL Accession No:AJ223219, XP002133317, see nts 3310-4600.
Armengaud (Nov. 1, 1998) “Flavin-binding monooxygenase-like”, PFAM Accession No:PF00743, XP002133310.
Armengaud (Nov. 1, 1998) “Putative Monooxygenase”, SWISSPROT Accession No:086908, XP002133318.
Bedzyk et al. (Jun. 15, 1993) “Paracoccus denitrificanselectron transfer flavoprotein alpha and beta subunit genes, complete cd's.”, EMBL Accession No:L14864, XP002130956 the whole document.

Affiliated with

Also associated with

Rating

Compositions and methods for fumonisin detoxification does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for fumonisin detoxification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for fumonisin detoxification will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3061280